BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34062328)

  • 1. An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells.
    Zhang J; Jain A; Milhas S; Williamson DJ; Mysliwy J; Lodge A; Thirlway J; Al Nakeeb M; Miller A; Rabbitts TH
    Leuk Res; 2021 Sep; 108():106626. PubMed ID: 34062328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL).
    Wang S; Zhang R; Zhong K; Guo W; Tong A
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
    Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
    J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ; Warnes SL; Noss AL; Flavell SU
    Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
    Smith RA; Zammit DJ; Damle NK; Usansky H; Reddy SP; Lin JH; Mistry M; Rao NS; Denis LJ; Gupta S
    Mol Cancer Ther; 2021 Aug; 20(8):1327-1337. PubMed ID: 34045226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.
    Fujita R; Blot V; Wong E; Stewart C; Lieuw V; Richardson R; Banah A; Villicana J; Timmer A; Coronella J; Newman R; Gymnopoulos M
    Cancer Biol Ther; 2020 Jun; 21(6):549-559. PubMed ID: 32192391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
    Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
    Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective
    Staudacher AH; Li Y; Liapis V; Hou JJC; Chin D; Dolezal O; Adams TE; van Berkel PH; Brown MP
    Mol Cancer Ther; 2019 Feb; 18(2):335-345. PubMed ID: 30413648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma.
    Sun F; Wang Y; Luo X; Ma Z; Xu Y; Zhang X; Lv T; Zhang Y; Wang M; Huang Z; Zhang J
    Cancer Res; 2019 Jul; 79(13):3395-3405. PubMed ID: 30918001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery.
    Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies.
    Kang X; Zhou L; Jian YM; Lan SA; Xu F
    Med Sci Monit; 2018 Mar; 24():1408-1416. PubMed ID: 29515096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
    Flavell DJ; Warnes S; Noss A; Flavell SU
    Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
    Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
    Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.
    Tang J; Li J; Zhu X; Yu Y; Chen D; Yuan L; Gu Z; Zhang X; Qi L; Gong Z; Jiang P; Yu J; Meng H; An G; Zheng H; Yang L
    Oncotarget; 2016 Jun; 7(23):34070-83. PubMed ID: 27083001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells.
    Ahmed N; Laverick L; Sammons J; Baumforth KR; Hassan HT
    Leuk Res; 1999 Aug; 23(8):741-9. PubMed ID: 10456672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
    Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
    Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
    Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
    Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.